Clinical trial of oxaliplatin injection and tegafur-gimeracil-oteracil potassium capsule in the treatment of late-stage triple-negative breast cancer
10.13699/j.cnki.1001-6821.2017.24.003
- VernacularTitle:奥利沙铂注射剂联合替吉奥胶囊治疗晚期三阴乳腺癌的临床研究
- Author:
Rui-Ping REN
1
;
Hui YANG
;
Zu-Guo YUAN
;
Yu ZHANG
;
Ji-Peng LI
Author Information
1. 鄞州人民医院肿瘤放化疗中心,浙江宁波315040
- Keywords:
oxaliplatin injection;
tegafur-gimeracil-oteracil potassium capsule;
gemcitabine injection;
cisplatin injection;
triple-negative breast cancer;
survival rate
- From:
The Chinese Journal of Clinical Pharmacology
2017;33(24):2566-2568
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the clinical efficacy and safety of oxaliplatin injection and tegafur-gimeracil-oteracil potassium capsule in the treatment of late-stage triple-negative breast cancer (TNBC).Methods A total of 120 patients with TNBC were randomly divided into control group(n =60)and treatment group (n =60).The control group received gemcitabine (1000 mg· m-2,intravenous drip,on the first day and the eighth day) and cisplatin (20 mg · m-2,intravenous drip,5 d).The treatment group received oxaliplatin (135 mg · m-2,intravenous drip,on the first day) and tegafur-gimeracil-oteracil potassium (40～60 mg,oral ad1ninistration,14 d).Both groups were treated for six 21-day cycles.If the disease progressed after six cycles,the treatment above will be replaced by other treatments.The clinical efficacy,and half year survival rate and the incidence of adverse drug reactions were compared between the two groups.Results After treatment,the overall response rates of the treatment group and the control group were 73.33％ (44 cases/60 cases) and 71.67％ (43 cases/60 cases),respectively,and no significant difference was found between the two groups (P ＞ 0.05).Six months after treatment,the survival rates of the treatment group and the control group were 85.00％ (51 cases/60 cases) and 81.67％ (49 cases/60 cases),with no significant difference (P ＞ 0.05);the adverse drug reactions in the treatment group and the control group were diarrhea,nausea and vomiting,and the incidences of adverse drug reactions were 18.33％ (11 cases/60 cases) and 21.67％ (13 cases/60 cases),respectively,and the difference was not significant (P ＞ 0.05).Conclusion Both combination treatment (oxaliplatin combined with tegafur-gimeracil-oteracil potassium,gemcitabine combined with cisplatin) exerted high clinical efficacy in the treatment of late-stage TNBC,and the six-month survival rates were high.
